GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Price-to-Owner-Earnings

SEOVF (Sernova Biotherapeutics) Price-to-Owner-Earnings : (As of Apr. 13, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Price-to-Owner-Earnings?

As of today (2025-04-13), Sernova Biotherapeutics's share price is $0.1261. Sernova Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sernova Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:


SEOVF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.005
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-13), Sernova Biotherapeutics's share price is $0.1261. Sernova Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.06. Therefore, Sernova Biotherapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-13), Sernova Biotherapeutics's share price is $0.1261. Sernova Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.06. Therefore, Sernova Biotherapeutics's PE Ratio without NRI for today is At Loss.


Sernova Biotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Sernova Biotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Price-to-Owner-Earnings Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sernova Biotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Sernova Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Price-to-Owner-Earnings falls into.


;
;

Sernova Biotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sernova Biotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1261/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics  (OTCPK:SEOVF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sernova Biotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.